Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02230176CT.gov Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Endocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxodotreotide (this asset) | Alliance for Clinical Trials in Oncology | P2 | B · 57 |
| Temsirolimus | University of Southern California | P2 | B |
| Carboplatin | ECOG-ACRIN Cancer Research Group | P2 | B |
| Everolimus | Emory University | P2 | B |
| Ziv-Aflibercept | National Cancer Institute (NCI) | P2 | B |
| Regorafenib | University of Southern California | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | Roswell Park Cancer Institute | P2 | B |
| Capecitabine | Alliance for Clinical Trials in Oncology | P2 | B |
+18 more in the Pancreatic Endocrine Carcinoma cohort
Other indications for Oxodotreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Neuroendocrine Tumor | — | P4 | BBB · 75 |
| Digestive System Neuroendocrine Neoplasm | — | P4 | BBB · 73 |
| Digestive System Neuroendocrine Tumor, Grade 1/2 | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxodotreotide in Pancreatic Endocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxodotreotide-pancreatic-endocrine-carcinoma-77457
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →